Volume Outpours: Orexigen Therapeutics (OREX), Jakks Pacific (JAKK), Crossroads Systems (CRDS), Bioline Rx (BLRX)

OREX, Orexigen Therapeutics, Technology
OREX, Orexigen Therapeutics, Technology

Orexigen Therapeutics, Inc. (OREX) Wednesday said fourth-quarter loss narrowed to $21.5 million or $0.21 per share from $32.5 million or $0.41 per share in the same period last year. On average, nine analysts polled by Thomson Reuters expected the company to report a loss of $0.19 per share for the quarter. Analysts’ estimates typically exclude special items. Revenues totaled $857 thousand, flat with last year.

Orexigen Therapeutics Inc (NASDAQ) stock volume flourished greedy buying over 124% with $6.33 average price trading 2,517,500 average volume shares. Orexigen Therapeutics Inc (NASDAQ : OREX), Specialty & Generic Drug Manufacturers company, shares after opening at $6.85 hit its intraday high price of $7.02 moreover then closed at $6.96 while shares flourished +3.73%. Company’s Beta (ß) of investment is 1.78 with $809.6 million market capitalization. Orexigen Therapeutics Inc recorded -52.60x return on assets (ROA) and 7.20x current ratio. We recommend to ‘Sell’ the stock.

JAKKS Pacific, Inc. (JAKK), a toys and other consumer products maker, reported Wednesday that its first-quarter net loss was $16.31 million or $0.74 per share, compared to a net loss of $27.56 million or $1.26 per share a year ago. On average, eight analysts polled by Thomson Reuters expected the company to report loss of $0.76 per share for the quarter.

Jakks Pacific Inc (NASDAQ) stock volume fostered greedy buying over 127% with $7.38 average price trading 417,800 average volume shares. On last trading day Jakks Pacific Inc (NASDAQ : JAKK), Leisure company, shares ended up $7.85, while trading in range of $7.77 and $8.00 by shares plunged -0.38%. Company’s Beta (ß) of investment is 0.23 with $172.7 million market capitalization. Jakks Pacific Inc recorded -10.40x return on assets (ROA) and 1.70x current ratio. Trade experts mull over it as ‘Sell’ stock.

Crossroads Systems Inc. (CRDS) Monday said it filed a complaint against Oracle Corp. (ORCL) in the federal district court in Austin, Texas, alleging infringement of U.S. Patents 6,425,035; 7,051,147; and 7,934,041. Crossroads seeks monetary damages and an injunction. Crossroads asserts that Oracle has incorporated Crossroads’ patented technology into Oracle’s storage systems, including its Pillar Axiom 300 and 600 systems, Sun Storage 2540-M2 Array, Solaris system, and Sun ZFS storage appliances.

Crossroads Systems Inc (NCM) stock volume boosted greedy buying over 119% with $2.43 average price trading 132,700 average volume shares. Crossroads Systems Inc (NCM : CRDS), Data Storage stock ended the day at $2.659, which thrived $0.149 (or +5.94%) and registered an intraday range of $2.34 and $2.80. Company’s Beta (ß) of investment is 0.68 with $40.0 million market capitalization. Crossroads Systems Inc recorded -94.40x return on assets (ROA) and 1.90x current ratio. Investment experts consider it a ‘Sell’ stock.

BioLineRx (BLRX), a clinical-stage biopharmaceutical company, announced Friday that it has signed a purchase agreement for the sale, from time to time, of up to $20 million of its American Depositary Shares, or ADSs with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor. During the 36-month term of the purchase agreement, BioLineRx controls the timing and amount of any sales to LPC, if and when the company decides, in accordance with the purchase agreement.

Bioline Rx Ltd (NCM) stock volume surged panic selling over 122% with $2.39 average price trading 188,200 average volume shares. Bioline Rx Ltd (NCM : BLRX), Biotechnology stock ended the day at $2.1801, which flourished $0.0701 (or +3.32%) and registered an intraday range of $2.15 and $2.3618. With 819629 of its shares exchanged hands during the day versus its average volume of 133459, market capitalization of Bioline Rx Ltd moved to 74.0 million. The float was recorded 0.00 million compared to 24.15 million outstanding shares.


Please enter your comment!
Please enter your name here